Immunodiagnostic Sys (IDH.L) Launch of SARS-CoV-2 Antigen Rapid Tests

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, announces that two SARS-CoV-2 Antigen Rapid Test kits are now available for sale in the UK, European Union and other countries which accept the CE mark as the basis of regulatory approval.

Both tests can be performed by a trained healthcare professional in community locations (e.g. workplaces, schools, doctors’ surgeries) without the need for any laboratory equipment. These tests determine the presence of the SARS-CoV-2 nucleocapsid protein antigen using direct nasopharyngeal swab samples, providing a result within 15 minutes.

Both fast and easy to use tests are based on the lateral flow principle: one in a cassette format, one in a test card format. These tests are provided by partners of IDS, and have been assessed by the manufacturers as having the following performance characteristics:

IDS now offers a comprehensive portfolio of SARS-CoV-2 antigen and antibody tests for the laboratory as well as for community locations; additional information of our SARS-CoV-2 assay portfolio can be found on the IDS website at .

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.